Who is sponsoring NCT05549921?

NCT05549921 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05549921?

Interventions in NCT05549921: NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy).

What condition does NCT05549921 study?

NCT05549921 studies Soft Tissue Sarcoma.

Is NCT05549921 still recruiting?

NCT05549921 is currently status unknown. Last updated 27 December 2023.

Last reviewed 2023-12-27 · How we verify

NCT05549921

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Status unknown Phase 2 Last updated 27 December 2023

What this trial tests

Phase 2 trial testing NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy) in Soft Tissue Sarcoma in 70 participants. Status unknown.

Timeline

8 July 2022

Primary endpoint
1 September 2024

1 September 2024

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	8 July 2022
Primary completion	1 September 2024
Estimated completion	1 September 2024
Sites	2 locations across China

Drugs / interventions tested

NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy) — full drug profile →

Conditions studied

Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 70, any sex, with Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this trial is to evaluate the efficacy and safety of TAEST16001 cells in the treatment of advanced soft tissue sarcoma patients with HLA-A\*02:01 tissue genotype and positive tumor antigen NY-ESO-1 expression.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

T cells in health and disease.
Sun L, Su Y, Jiao A, Wang X, et al · · 2023 · cited 717× · PMID 37332039 · DOI 10.1038/s41392-023-01471-y
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.
Li J, Xiao Z, Wang D, Jia L, et al · · 2023 · cited 52× · PMID 37649123 · DOI 10.1186/s12943-023-01844-5
Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer.
Nin DS, Deng LW. · · 2023 · cited 45× · PMID 36980267 · DOI 10.3390/cells12060926
T cells in cancer: mechanistic insights and therapeutic advances.
Pu J, Liu T, Zhou Y, Chen M, et al · · 2025 · cited 6× · PMID 40660400 · DOI 10.1186/s40364-025-00807-w
Gene and Cell Therapy for Sarcomas: A Review.
Chawla SP, Pang SS, Jain D, Jeffrey S, et al · · 2025 · PMID 40227707 · DOI 10.3390/cancers17071125

Verify or expand the search:

Other recruiting trials for Soft Tissue Sarcoma

Currently open trials in the same condition.

NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
NCT07243626 — Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma · Phase 2 · recruiting
NCT07049848 — SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radi · Phase 2 · recruiting
NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
NCT06905132 — Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05549921 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 27 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05549921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing